Risk factors associated with calcinosis of juvenile dermatomyositis;Fatores de risco associados à calcinose na dermatomiosite juvenil

Jornal de Pediatria

Volumn 84, Issue 1, 2008, Pages 68-74

  Sallum, Adriana Maluf Elias ^a,b   Pivato, Francine C M M ^a   Doria Filho, Ulysses ^a   Aikawa, Nádia E ^a   Liphaus, Bernadete L ^a   Marie, Suely K N ^a   Silva, Clovis A A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b USP ^*  (Brazil)

Author keywords

Calcinosis; Heart; Immunosuppressors; Juvenile dermatomyositis; Lungs; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHLOROQUINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; HYDROXYCHLOROQUINE SULFATE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCINOSIS; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEMOGRAPHY; DERMATOMYOSITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; MUSCLE STRENGTH; MYOCARDITIS; PERICARDITIS; RISK; RISK FACTOR; UNIVARIATE ANALYSIS;

EID: 39649108172     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1746     Document Type: Article

References (37)

1. Cassidy JT, Lindsley CB. Juvenile dermatomyositis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005. p. 407-41.
2. Ansell BM. Juvenile dermatomyositis. Rheum Dis Clin North Am. 1991;17:931-42.
3. Ansell BM. Juvenile dermatomyositis. J Rheumatol Suppl. 1992;33:60-2.
4. Mastaglia FL, Ojeda VJ. Inflammatory myopathies: Part 1. Ann Neurol. 1985;17:215-27.
5. Mastaglia FL, Ojeda VJ. Inflammatory myopathies: Part 2. Ann Neurol. 1985;17:317-23.
6. Miller FW. Inflammatory myopathies. Annual Review Course 55th Annual Scientific Meeting; 1991 Nov; Boston: Massachussets; 1991.
7. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Disease Registry. Arthritis Rheum. 2003;49:300-5.
8. Sogabe T, Silva CA, Kiss MHB. Clinical and laboratory characteristics of 50 children with dermato/polymyositis. Rev Bras Reumatol. 1996;36:351-9.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7.
10. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103:882-8.
11. Sallum AM, Kiss MH, Sachetti S, Resende MB, Moutinho KC, Carvalho Mde S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr. 2002;60:889-99.
12. Plotz PH, Rider LG, Tragoff IN, Raben N, O'Hanlon TP, Miller FW. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann intern Med. 1995;122:715-724.
13. Pachman LM, Boskey AL. Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep. 2006;8:236-43.
14. Crowe WE. Dermatomyositis and polymiositis In: Gershwin ME, Robbins DL. Musculoskeletal diseases of children. New York: Grune & Stratton; 1983. p. 113-37.
15. Burgos-Vargas R, Vasquez-Mellado J, Gomez-Gordillo Y, Katona G. Estudio clinico de la polidermatomiositis de inicio en la enfancia. Bol Med Hosp Infant Mex. 1987;44:463-70.
16. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila). 1987;26:561-6.
17. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47:505-11.
18. Rider LG. Calcinosis in juvenile dermatomyositis: pathogenesis and current therapies. Pediatric Rheumatology Online Journal. http://www. pedrheumonlinejournal.org. Access: 23/07/2007.
19. Medical Research Council. Aids to the investigation of peripheral nerve injuries. 2nd ed. London: Majesty's Stationery; 1943.
20. Black AS, Kanat IO. A review of soft tissue calcifications. J Foot Surg. 1985;24:243-50.
21. Wananukul S, Pongprasit P, Wattanakrai P. Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two years. Australas J Dermatol. 1997;38:202-5.
22. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138:763-6.
23. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43:2368-77.
24. Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum. 2006;54:3345-50.
25. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148:247-53.
26. Romero KT, Terreri MT, Len CA, Hilário MO. Dermatomiosite e polimiosite juvenis: diagnóstico e tratamento. Rev Paul Pediatria. 2003;21:223-7.
27. Pilkington CA, Wedderburn LR. Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs. 2005;65:1355-65.
28. Compeyrot-Lacassagne S, Feldman BM. Inflammatory myopathies in children. Pediatr Clin North Am. 2005;52:493-520, vi-vii.
29. Ostrov BE, Goldsmith DP, Eichenfield AH, Athreya BH. Hypercalcemia during the resolution of calcinosis universalis in juvenile dermatomyositis. J Rheumatol. 1991;18:1730-4.
30. Reed AM, Lopez M. Juvenile dermatomyositis: recognition and treatment. Paediatr Drugs. 2002;4:315-21.
31. Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol. 2006;18:503-6.
32. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52:3570-8.
33. Castro TC, Yamashita E, Terreri MT, Len CA, Hilário MO. Calcinose na infância, um desafio terapêutico. Rev Bras Reumatol. 2007;47:63-8.
34. Downey EC Jr., Woolley MM, Hanson V. Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg. 1988;123:1117-20.
35. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49:7-15.
36. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004;50:1595-603.
37. Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45:990-3.